| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Typhoid Fever | 44 | 2023 | 46 | 13.100 |
Why?
|
| Disease Outbreaks | 52 | 2023 | 155 | 10.580 |
Why?
|
| Cholera | 40 | 2023 | 70 | 10.190 |
Why?
|
| Diarrhea | 46 | 2023 | 84 | 7.610 |
Why?
|
| Salmonella typhi | 31 | 2023 | 33 | 7.150 |
Why?
|
| Sanitation | 20 | 2023 | 27 | 4.350 |
Why?
|
| Water Supply | 22 | 2023 | 54 | 3.530 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 11 | 2020 | 11 | 3.370 |
Why?
|
| Child, Preschool | 75 | 2023 | 1318 | 3.150 |
Why?
|
| Travel | 15 | 2021 | 32 | 2.680 |
Why?
|
| Anti-Bacterial Agents | 26 | 2023 | 355 | 2.680 |
Why?
|
| Infant | 60 | 2023 | 1014 | 2.460 |
Why?
|
| Feces | 24 | 2023 | 110 | 2.310 |
Why?
|
| Cholera Vaccines | 10 | 2023 | 18 | 2.120 |
Why?
|
| Water Purification | 10 | 2020 | 27 | 2.090 |
Why?
|
| Child | 58 | 2023 | 2875 | 1.930 |
Why?
|
| Salmonella Infections | 7 | 2021 | 16 | 1.910 |
Why?
|
| Humans | 156 | 2023 | 34853 | 1.900 |
Why?
|
| Dysentery, Bacillary | 11 | 2015 | 13 | 1.890 |
Why?
|
| Vibrio cholerae O1 | 6 | 2018 | 11 | 1.840 |
Why?
|
| Case-Control Studies | 36 | 2023 | 1056 | 1.700 |
Why?
|
| Paratyphoid Fever | 7 | 2018 | 7 | 1.660 |
Why?
|
| Water Microbiology | 14 | 2020 | 72 | 1.570 |
Why?
|
| Kenya | 29 | 2023 | 51 | 1.520 |
Why?
|
| Hygiene | 8 | 2020 | 14 | 1.510 |
Why?
|
| Drug Resistance, Bacterial | 9 | 2016 | 78 | 1.450 |
Why?
|
| Escherichia coli Infections | 8 | 2023 | 39 | 1.380 |
Why?
|
| Endemic Diseases | 3 | 2016 | 22 | 1.370 |
Why?
|
| Female | 84 | 2023 | 19873 | 1.350 |
Why?
|
| Population Surveillance | 16 | 2018 | 231 | 1.330 |
Why?
|
| Vaccination | 7 | 2015 | 259 | 1.330 |
Why?
|
| Male | 82 | 2023 | 18870 | 1.300 |
Why?
|
| Adolescent | 50 | 2020 | 5035 | 1.270 |
Why?
|
| Adult | 62 | 2021 | 11034 | 1.200 |
Why?
|
| Middle Aged | 52 | 2020 | 9642 | 1.080 |
Why?
|
| Young Adult | 33 | 2020 | 4012 | 1.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 7 | 2020 | 30 | 0.990 |
Why?
|
| Cryptosporidiosis | 6 | 2023 | 6 | 0.990 |
Why?
|
| Ceftriaxone | 2 | 2021 | 11 | 0.970 |
Why?
|
| Fever | 4 | 2021 | 57 | 0.960 |
Why?
|
| Salmonella | 2 | 2021 | 13 | 0.960 |
Why?
|
| Microbial Sensitivity Tests | 16 | 2022 | 203 | 0.950 |
Why?
|
| Risk Factors | 28 | 2023 | 3414 | 0.950 |
Why?
|
| Aged, 80 and over | 22 | 2020 | 2333 | 0.940 |
Why?
|
| Incidence | 21 | 2023 | 882 | 0.930 |
Why?
|
| Aged | 35 | 2020 | 6448 | 0.930 |
Why?
|
| Family Characteristics | 8 | 2018 | 102 | 0.900 |
Why?
|
| Infant, Newborn | 23 | 2023 | 871 | 0.900 |
Why?
|
| Rural Population | 13 | 2018 | 253 | 0.900 |
Why?
|
| Food Microbiology | 11 | 2020 | 34 | 0.890 |
Why?
|
| Shigella | 6 | 2021 | 10 | 0.870 |
Why?
|
| Foodborne Diseases | 6 | 2014 | 22 | 0.850 |
Why?
|
| United States | 26 | 2021 | 3894 | 0.830 |
Why?
|
| Haiti | 13 | 2017 | 59 | 0.800 |
Why?
|
| Drug Resistance, Microbial | 2 | 2020 | 26 | 0.790 |
Why?
|
| Escherichia coli | 11 | 2021 | 436 | 0.770 |
Why?
|
| Sepsis | 1 | 2021 | 76 | 0.750 |
Why?
|
| Rotavirus Infections | 6 | 2023 | 15 | 0.730 |
Why?
|
| Uganda | 7 | 2021 | 22 | 0.680 |
Why?
|
| Communicable Disease Control | 3 | 2013 | 31 | 0.670 |
Why?
|
| Funeral Rites | 1 | 2018 | 1 | 0.670 |
Why?
|
| Cryptosporidium | 4 | 2023 | 4 | 0.650 |
Why?
|
| Financing, Personal | 1 | 2017 | 9 | 0.640 |
Why?
|
| Vibrio cholerae | 7 | 2018 | 98 | 0.630 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 9 | 2014 | 27 | 0.620 |
Why?
|
| Health Expenditures | 1 | 2017 | 30 | 0.620 |
Why?
|
| Disease Transmission, Infectious | 3 | 2013 | 29 | 0.590 |
Why?
|
| Enteritis | 1 | 2016 | 4 | 0.570 |
Why?
|
| Cholera Toxin | 2 | 2008 | 34 | 0.570 |
Why?
|
| Cost of Illness | 6 | 2016 | 79 | 0.560 |
Why?
|
| Time Factors | 12 | 2020 | 1681 | 0.550 |
Why?
|
| Africa | 9 | 2019 | 62 | 0.550 |
Why?
|
| Urban Health | 1 | 2016 | 86 | 0.540 |
Why?
|
| Developing Countries | 9 | 2019 | 97 | 0.540 |
Why?
|
| Shigella flexneri | 4 | 2015 | 6 | 0.530 |
Why?
|
| World Health Organization | 6 | 2015 | 30 | 0.530 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 254 | 0.520 |
Why?
|
| Malawi | 4 | 2018 | 9 | 0.510 |
Why?
|
| Laboratories | 4 | 2022 | 36 | 0.510 |
Why?
|
| Topography, Medical | 1 | 2014 | 2 | 0.500 |
Why?
|
| Logistic Models | 10 | 2020 | 894 | 0.490 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2013 | 6 | 0.490 |
Why?
|
| Africa South of the Sahara | 10 | 2019 | 43 | 0.480 |
Why?
|
| Cluster Analysis | 5 | 2019 | 188 | 0.480 |
Why?
|
| Food Contamination | 4 | 2017 | 55 | 0.470 |
Why?
|
| Pakistan | 3 | 2022 | 21 | 0.460 |
Why?
|
| Shigella sonnei | 4 | 2009 | 5 | 0.460 |
Why?
|
| Hospitalization | 6 | 2016 | 370 | 0.450 |
Why?
|
| Nervous System | 1 | 2012 | 29 | 0.450 |
Why?
|
| Child Mortality | 1 | 2012 | 11 | 0.440 |
Why?
|
| Disasters | 4 | 2014 | 64 | 0.440 |
Why?
|
| Doxycycline | 1 | 2012 | 30 | 0.440 |
Why?
|
| Vaccines | 2 | 2023 | 49 | 0.430 |
Why?
|
| Leptospira | 1 | 2012 | 22 | 0.430 |
Why?
|
| Intestinal Perforation | 1 | 2012 | 10 | 0.430 |
Why?
|
| Leptospirosis | 1 | 2012 | 26 | 0.430 |
Why?
|
| Immunization Programs | 4 | 2017 | 22 | 0.430 |
Why?
|
| Sensitivity and Specificity | 8 | 2015 | 555 | 0.420 |
Why?
|
| Zimbabwe | 4 | 2019 | 5 | 0.410 |
Why?
|
| Health Personnel | 1 | 2013 | 200 | 0.410 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 66 | 0.410 |
Why?
|
| Halogenation | 1 | 2011 | 19 | 0.410 |
Why?
|
| Bacteremia | 4 | 2019 | 31 | 0.400 |
Why?
|
| Fishes | 1 | 2011 | 48 | 0.390 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2015 | 47 | 0.380 |
Why?
|
| Odds Ratio | 11 | 2020 | 517 | 0.380 |
Why?
|
| Fluid Therapy | 6 | 2013 | 27 | 0.380 |
Why?
|
| Disinfection | 2 | 2007 | 8 | 0.380 |
Why?
|
| Anti-Infective Agents | 3 | 2012 | 62 | 0.380 |
Why?
|
| Soaps | 3 | 2020 | 3 | 0.380 |
Why?
|
| Chlorine | 6 | 2020 | 8 | 0.370 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2018 | 790 | 0.370 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 608 | 0.370 |
Why?
|
| Norovirus | 5 | 2023 | 10 | 0.350 |
Why?
|
| Vibrio cholerae non-O1 | 1 | 2008 | 2 | 0.340 |
Why?
|
| Ciprofloxacin | 4 | 2023 | 15 | 0.330 |
Why?
|
| Rotavirus | 4 | 2023 | 11 | 0.320 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 375 | 0.320 |
Why?
|
| Shigella dysenteriae | 1 | 2007 | 1 | 0.310 |
Why?
|
| Shiga Toxin 1 | 1 | 2007 | 3 | 0.310 |
Why?
|
| Restaurants | 6 | 2008 | 35 | 0.310 |
Why?
|
| Urban Population | 5 | 2020 | 318 | 0.310 |
Why?
|
| Age Distribution | 5 | 2013 | 223 | 0.300 |
Why?
|
| Salmonella paratyphi A | 4 | 2018 | 4 | 0.290 |
Why?
|
| Equipment Contamination | 1 | 2006 | 5 | 0.290 |
Why?
|
| Asia | 5 | 2019 | 74 | 0.290 |
Why?
|
| Disaster Planning | 1 | 2007 | 51 | 0.280 |
Why?
|
| Serotyping | 6 | 2014 | 36 | 0.280 |
Why?
|
| Metals | 1 | 2006 | 95 | 0.270 |
Why?
|
| Diarrhea, Infantile | 3 | 2013 | 5 | 0.260 |
Why?
|
| Clinical Competence | 1 | 2006 | 124 | 0.260 |
Why?
|
| Dysentery | 2 | 2019 | 2 | 0.260 |
Why?
|
| Cattle | 2 | 2023 | 472 | 0.260 |
Why?
|
| Enterotoxigenic Escherichia coli | 2 | 2019 | 5 | 0.260 |
Why?
|
| Sentinel Surveillance | 2 | 2015 | 20 | 0.260 |
Why?
|
| Rotavirus Vaccines | 2 | 2023 | 12 | 0.250 |
Why?
|
| Fresh Water | 1 | 2004 | 47 | 0.250 |
Why?
|
| Health Education | 4 | 2020 | 304 | 0.240 |
Why?
|
| Animals | 14 | 2023 | 14307 | 0.240 |
Why?
|
| Serologic Tests | 1 | 2004 | 43 | 0.240 |
Why?
|
| HIV Infections | 6 | 2018 | 2207 | 0.240 |
Why?
|
| Administration, Oral | 4 | 2017 | 212 | 0.240 |
Why?
|
| Enteropathogenic Escherichia coli | 1 | 2023 | 3 | 0.230 |
Why?
|
| Ethiopia | 1 | 2023 | 9 | 0.230 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 1 | 2023 | 5 | 0.230 |
Why?
|
| Shellfish | 2 | 2014 | 13 | 0.230 |
Why?
|
| Bacteria | 1 | 2006 | 245 | 0.230 |
Why?
|
| Quinolones | 1 | 2022 | 7 | 0.220 |
Why?
|
| Mozambique | 2 | 2012 | 3 | 0.220 |
Why?
|
| Enterobacteriaceae | 3 | 2013 | 26 | 0.210 |
Why?
|
| Growth Disorders | 1 | 2021 | 22 | 0.210 |
Why?
|
| Salmonella enterica | 3 | 2015 | 8 | 0.210 |
Why?
|
| Gastroenteritis | 3 | 2007 | 17 | 0.210 |
Why?
|
| Child, Hospitalized | 1 | 2021 | 1 | 0.210 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2003 | 165 | 0.200 |
Why?
|
| Public Health | 5 | 2018 | 348 | 0.200 |
Why?
|
| Bacterial Infections | 3 | 2013 | 44 | 0.200 |
Why?
|
| Guinea-Bissau | 2 | 2011 | 2 | 0.190 |
Why?
|
| Iraq | 1 | 2020 | 6 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 5 | 2019 | 430 | 0.190 |
Why?
|
| Communicable Diseases | 2 | 2018 | 42 | 0.190 |
Why?
|
| Prevalence | 7 | 2019 | 1425 | 0.190 |
Why?
|
| Glass | 2 | 2009 | 15 | 0.180 |
Why?
|
| Filtration | 2 | 2018 | 14 | 0.180 |
Why?
|
| Dominican Republic | 2 | 2011 | 20 | 0.180 |
Why?
|
| Carrier State | 1 | 2019 | 32 | 0.180 |
Why?
|
| Thrombectomy | 1 | 2019 | 12 | 0.180 |
Why?
|
| Antibodies, Bacterial | 3 | 2012 | 107 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 142 | 0.180 |
Why?
|
| Silver | 2 | 2009 | 53 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2009 | 41 | 0.170 |
Why?
|
| Fimbriae Proteins | 1 | 2019 | 18 | 0.170 |
Why?
|
| Health Services Research | 1 | 2019 | 133 | 0.170 |
Why?
|
| DNA, Bacterial | 3 | 2008 | 184 | 0.170 |
Why?
|
| Ceramics | 1 | 2018 | 4 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2019 | 1353 | 0.160 |
Why?
|
| Security Measures | 1 | 2018 | 2 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 424 | 0.160 |
Why?
|
| Virulence Factors | 1 | 2019 | 113 | 0.160 |
Why?
|
| Toilet Facilities | 1 | 2017 | 2 | 0.160 |
Why?
|
| Animals, Domestic | 1 | 2017 | 8 | 0.160 |
Why?
|
| Government Programs | 1 | 2017 | 28 | 0.160 |
Why?
|
| Homosexuality, Male | 1 | 2003 | 438 | 0.160 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 54 | 0.160 |
Why?
|
| Refugees | 1 | 2017 | 14 | 0.150 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 570 | 0.150 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2009 | 21 | 0.150 |
Why?
|
| Capacity Building | 1 | 2018 | 78 | 0.150 |
Why?
|
| Poverty | 1 | 2019 | 316 | 0.150 |
Why?
|
| Perception | 2 | 2017 | 183 | 0.150 |
Why?
|
| Metal Nanoparticles | 2 | 2009 | 180 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2017 | 136 | 0.150 |
Why?
|
| Blood | 2 | 2014 | 32 | 0.140 |
Why?
|
| Agglutination Tests | 2 | 2014 | 5 | 0.140 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2015 | 22 | 0.140 |
Why?
|
| Food Handling | 3 | 2012 | 33 | 0.140 |
Why?
|
| Immunoassay | 2 | 2016 | 57 | 0.140 |
Why?
|
| Seasons | 1 | 2016 | 112 | 0.140 |
Why?
|
| Polysaccharides, Bacterial | 2 | 2014 | 12 | 0.140 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 37 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 41 | 0.140 |
Why?
|
| Hospitals, Psychiatric | 1 | 2015 | 14 | 0.140 |
Why?
|
| Survival Rate | 2 | 2016 | 310 | 0.140 |
Why?
|
| Zambia | 3 | 2020 | 37 | 0.140 |
Why?
|
| Earthquakes | 2 | 2013 | 6 | 0.130 |
Why?
|
| Interviews as Topic | 2 | 2014 | 356 | 0.130 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 132 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 51 | 0.130 |
Why?
|
| Cross Infection | 1 | 2015 | 38 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2014 | 2561 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2017 | 283 | 0.130 |
Why?
|
| Shigella Vaccines | 1 | 2014 | 1 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2015 | 82 | 0.130 |
Why?
|
| Area Under Curve | 1 | 2014 | 91 | 0.130 |
Why?
|
| Caliciviridae Infections | 2 | 2004 | 7 | 0.120 |
Why?
|
| Infant Mortality | 1 | 2014 | 57 | 0.120 |
Why?
|
| Antigens, Bacterial | 2 | 2006 | 129 | 0.120 |
Why?
|
| Sanitary Engineering | 1 | 2013 | 2 | 0.120 |
Why?
|
| Brachyura | 1 | 2014 | 14 | 0.120 |
Why?
|
| Molecular Epidemiology | 2 | 2016 | 49 | 0.120 |
Why?
|
| Biosurveillance | 1 | 2013 | 1 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2014 | 77 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 30 | 0.110 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 16 | 0.110 |
Why?
|
| Cyclonic Storms | 1 | 2014 | 62 | 0.110 |
Why?
|
| Guyana | 1 | 2012 | 1 | 0.110 |
Why?
|
| Pregnancy | 2 | 2016 | 1503 | 0.110 |
Why?
|
| Floods | 1 | 2012 | 6 | 0.110 |
Why?
|
| Vibrio mimicus | 1 | 2012 | 1 | 0.110 |
Why?
|
| Vibrio Infections | 1 | 2012 | 4 | 0.110 |
Why?
|
| Astacoidea | 1 | 2012 | 3 | 0.110 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2012 | 11 | 0.110 |
Why?
|
| Mammea | 1 | 2012 | 1 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2013 | 159 | 0.110 |
Why?
|
| Guatemala | 4 | 2019 | 17 | 0.110 |
Why?
|
| Genotype | 2 | 2019 | 641 | 0.110 |
Why?
|
| Drug Resistance, Multiple | 2 | 2017 | 26 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2013 | 322 | 0.110 |
Why?
|
| DNA Fingerprinting | 2 | 2008 | 18 | 0.110 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2011 | 342 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2012 | 81 | 0.100 |
Why?
|
| Health Policy | 1 | 2013 | 149 | 0.100 |
Why?
|
| Asia, Western | 3 | 2018 | 4 | 0.100 |
Why?
|
| Environmental Monitoring | 3 | 2007 | 188 | 0.100 |
Why?
|
| Guam | 1 | 2011 | 76 | 0.100 |
Why?
|
| Caregivers | 1 | 2013 | 167 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 187 | 0.100 |
Why?
|
| Fruit | 1 | 2012 | 159 | 0.100 |
Why?
|
| Housing | 2 | 2007 | 54 | 0.090 |
Why?
|
| Ohio | 3 | 2007 | 13 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 859 | 0.090 |
Why?
|
| Enterotoxins | 2 | 2008 | 32 | 0.090 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2009 | 14 | 0.090 |
Why?
|
| Politics | 1 | 2009 | 35 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 468 | 0.090 |
Why?
|
| Mali | 2 | 2023 | 3 | 0.090 |
Why?
|
| History, 19th Century | 1 | 2009 | 24 | 0.090 |
Why?
|
| Southeastern United States | 1 | 2008 | 48 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2009 | 110 | 0.080 |
Why?
|
| Seafood | 1 | 2008 | 19 | 0.080 |
Why?
|
| Salmonella paratyphi C | 1 | 2008 | 1 | 0.080 |
Why?
|
| Salmonella paratyphi B | 1 | 2008 | 1 | 0.080 |
Why?
|
| Violence | 1 | 2009 | 126 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2008 | 1422 | 0.080 |
Why?
|
| Child Day Care Centers | 2 | 2009 | 10 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2008 | 6 | 0.080 |
Why?
|
| Case Management | 1 | 2008 | 21 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2008 | 93 | 0.080 |
Why?
|
| Relief Work | 1 | 2007 | 7 | 0.080 |
Why?
|
| Water Pollutants | 1 | 2007 | 17 | 0.080 |
Why?
|
| Louisiana | 1 | 2007 | 39 | 0.080 |
Why?
|
| Respiratory Tract Diseases | 1 | 2007 | 25 | 0.080 |
Why?
|
| Eating | 2 | 2014 | 152 | 0.080 |
Why?
|
| Asia, Southeastern | 2 | 2018 | 11 | 0.070 |
Why?
|
| Humidity | 1 | 2006 | 10 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2014 | 151 | 0.070 |
Why?
|
| Hot Temperature | 1 | 2007 | 120 | 0.070 |
Why?
|
| Colony Count, Microbial | 1 | 2006 | 66 | 0.070 |
Why?
|
| Trimethoprim Resistance | 1 | 2006 | 1 | 0.070 |
Why?
|
| Ampicillin Resistance | 1 | 2006 | 3 | 0.070 |
Why?
|
| Ampicillin | 1 | 2006 | 5 | 0.070 |
Why?
|
| Illinois | 1 | 2005 | 9 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2006 | 469 | 0.070 |
Why?
|
| New York | 1 | 2005 | 69 | 0.070 |
Why?
|
| Poliomyelitis | 2 | 2017 | 7 | 0.070 |
Why?
|
| Influenza in Birds | 2 | 2017 | 10 | 0.070 |
Why?
|
| India | 2 | 2016 | 82 | 0.070 |
Why?
|
| Birds | 2 | 2017 | 30 | 0.070 |
Why?
|
| Mortality | 2 | 2019 | 150 | 0.070 |
Why?
|
| Hospitals | 2 | 2018 | 86 | 0.070 |
Why?
|
| Texas | 1 | 2006 | 299 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2020 | 1961 | 0.060 |
Why?
|
| Shigella boydii | 1 | 2004 | 1 | 0.060 |
Why?
|
| Mass Vaccination | 2 | 2016 | 7 | 0.060 |
Why?
|
| Ships | 1 | 2004 | 7 | 0.060 |
Why?
|
| Naval Medicine | 1 | 2004 | 1 | 0.060 |
Why?
|
| Vietnam | 1 | 2004 | 38 | 0.060 |
Why?
|
| Beverages | 2 | 2017 | 64 | 0.060 |
Why?
|
| Conservation of Natural Resources | 1 | 2004 | 32 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 282 | 0.060 |
Why?
|
| Hepatitis A | 1 | 2004 | 10 | 0.060 |
Why?
|
| Kentucky | 1 | 2003 | 2 | 0.060 |
Why?
|
| Indiana | 1 | 2003 | 15 | 0.060 |
Why?
|
| Gambia | 1 | 2023 | 1 | 0.060 |
Why?
|
| Petroselinum | 1 | 2003 | 4 | 0.060 |
Why?
|
| Public Health Practice | 2 | 2018 | 38 | 0.060 |
Why?
|
| Giardia | 1 | 2023 | 13 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 26 | 0.060 |
Why?
|
| Cough | 1 | 2023 | 17 | 0.060 |
Why?
|
| Helicobacter Infections | 1 | 2004 | 74 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 531 | 0.060 |
Why?
|
| Chloramphenicol | 1 | 2022 | 5 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 901 | 0.050 |
Why?
|
| Infant Food | 1 | 2002 | 14 | 0.050 |
Why?
|
| Reproduction | 1 | 2002 | 63 | 0.050 |
Why?
|
| Salmonella typhimurium | 1 | 2021 | 40 | 0.050 |
Why?
|
| Water | 1 | 2004 | 283 | 0.050 |
Why?
|
| Nevada | 2 | 2012 | 6 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2009 | 138 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 2 | 2013 | 67 | 0.040 |
Why?
|
| Community-Acquired Infections | 1 | 2019 | 24 | 0.040 |
Why?
|
| Bangladesh | 2 | 2010 | 20 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 37 | 0.040 |
Why?
|
| Health Surveys | 2 | 2013 | 358 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 182 | 0.040 |
Why?
|
| Chile | 1 | 2018 | 6 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2015 | 727 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 612 | 0.040 |
Why?
|
| California | 2 | 2012 | 436 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2002 | 418 | 0.040 |
Why?
|
| Yellow Fever | 1 | 2017 | 4 | 0.040 |
Why?
|
| Sheep, Domestic | 1 | 2017 | 7 | 0.040 |
Why?
|
| Animal Husbandry | 1 | 2017 | 14 | 0.040 |
Why?
|
| Research Design | 1 | 2019 | 292 | 0.040 |
Why?
|
| Zoonoses | 1 | 2017 | 19 | 0.040 |
Why?
|
| Rodentia | 1 | 2017 | 41 | 0.040 |
Why?
|
| Pediatrics | 1 | 2018 | 66 | 0.040 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2017 | 29 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2017 | 28 | 0.040 |
Why?
|
| Water Pollution | 1 | 2017 | 10 | 0.040 |
Why?
|
| Data Collection | 1 | 2018 | 188 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 964 | 0.040 |
Why?
|
| Melanesia | 1 | 2016 | 22 | 0.040 |
Why?
|
| Gram-Negative Bacteria | 2 | 2009 | 22 | 0.040 |
Why?
|
| Vomiting | 1 | 2016 | 13 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2016 | 42 | 0.040 |
Why?
|
| Afghanistan | 1 | 2016 | 7 | 0.040 |
Why?
|
| Chickens | 1 | 2017 | 123 | 0.040 |
Why?
|
| Parents | 1 | 2019 | 288 | 0.040 |
Why?
|
| Data Mining | 1 | 2016 | 21 | 0.040 |
Why?
|
| Focus Groups | 1 | 2017 | 307 | 0.040 |
Why?
|
| Cryptosporidium parvum | 2 | 2007 | 3 | 0.040 |
Why?
|
| Coronavirus Infections | 1 | 2017 | 63 | 0.040 |
Why?
|
| Cambodia | 1 | 2015 | 3 | 0.030 |
Why?
|
| Diet | 1 | 2002 | 747 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2015 | 74 | 0.030 |
Why?
|
| American Samoa | 1 | 2015 | 16 | 0.030 |
Why?
|
| Health Resources | 1 | 2015 | 32 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 94 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 628 | 0.030 |
Why?
|
| Fiji | 1 | 2014 | 1 | 0.030 |
Why?
|
| Bacterial Typing Techniques | 1 | 2014 | 34 | 0.030 |
Why?
|
| Pacific Islands | 1 | 2014 | 115 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 1300 | 0.030 |
Why?
|
| Sierra Leone | 1 | 2014 | 3 | 0.030 |
Why?
|
| Enterovirus A, Human | 1 | 2013 | 1 | 0.030 |
Why?
|
| Markov Chains | 1 | 2013 | 32 | 0.030 |
Why?
|
| Poliovirus | 1 | 2013 | 5 | 0.030 |
Why?
|
| Enterovirus Infections | 1 | 2013 | 4 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 30 | 0.030 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2013 | 7 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 301 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 55 | 0.030 |
Why?
|
| Inpatients | 1 | 2013 | 72 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2013 | 56 | 0.030 |
Why?
|
| Washington | 1 | 2012 | 28 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 445 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 12 | 0.030 |
Why?
|
| Oregon | 1 | 2012 | 39 | 0.030 |
Why?
|
| Contact Tracing | 1 | 2012 | 17 | 0.030 |
Why?
|
| Emergencies | 1 | 2011 | 23 | 0.030 |
Why?
|
| Middle East | 1 | 2011 | 18 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2015 | 285 | 0.030 |
Why?
|
| Europe | 1 | 2011 | 88 | 0.030 |
Why?
|
| DNA Topoisomerase IV | 1 | 2011 | 2 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2013 | 288 | 0.030 |
Why?
|
| DNA Gyrase | 1 | 2011 | 7 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2013 | 183 | 0.030 |
Why?
|
| Malaria | 1 | 2012 | 68 | 0.030 |
Why?
|
| Quality of Life | 1 | 2015 | 459 | 0.020 |
Why?
|
| Botswana | 1 | 2010 | 5 | 0.020 |
Why?
|
| Infant Formula | 1 | 2010 | 13 | 0.020 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2011 | 145 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2012 | 207 | 0.020 |
Why?
|
| Photoelectron Spectroscopy | 1 | 2009 | 5 | 0.020 |
Why?
|
| Missouri | 1 | 2009 | 7 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2010 | 37 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2009 | 49 | 0.020 |
Why?
|
| Infection Control | 1 | 2009 | 13 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2010 | 105 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 143 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2009 | 69 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2008 | 28 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2009 | 150 | 0.020 |
Why?
|
| Antimalarials | 1 | 2008 | 48 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2008 | 44 | 0.020 |
Why?
|
| Flocculation | 1 | 2007 | 6 | 0.020 |
Why?
|
| Disinfectants | 1 | 2007 | 7 | 0.020 |
Why?
|
| Giardia lamblia | 1 | 2007 | 29 | 0.020 |
Why?
|
| Malaria, Falciparum | 1 | 2008 | 81 | 0.020 |
Why?
|
| Plasmodium falciparum | 1 | 2008 | 121 | 0.020 |
Why?
|
| Campylobacter jejuni | 1 | 2007 | 21 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 2008 | 119 | 0.020 |
Why?
|
| China | 1 | 2007 | 178 | 0.020 |
Why?
|
| Geography | 1 | 2007 | 86 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1023 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2007 | 212 | 0.020 |
Why?
|
| O Antigens | 1 | 2006 | 5 | 0.020 |
Why?
|
| Tennessee | 1 | 2006 | 59 | 0.020 |
Why?
|
| Schools | 1 | 2007 | 229 | 0.020 |
Why?
|
| Parasitic Diseases | 1 | 2004 | 6 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2004 | 21 | 0.020 |
Why?
|
| Recreation | 1 | 2004 | 29 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 219 | 0.020 |
Why?
|
| Hepatitis A virus | 1 | 2004 | 2 | 0.020 |
Why?
|
| Viral Vaccines | 1 | 2004 | 28 | 0.020 |
Why?
|
| Hydrotherapy | 1 | 2003 | 1 | 0.020 |
Why?
|
| Acute Disease | 1 | 2004 | 141 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2008 | 1349 | 0.010 |
Why?
|
| HIV-1 | 1 | 2009 | 678 | 0.010 |
Why?
|
| Micronesia | 1 | 2003 | 87 | 0.010 |
Why?
|
| Diapers, Infant | 1 | 2003 | 1 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2004 | 114 | 0.010 |
Why?
|
| Minnesota | 1 | 2003 | 39 | 0.010 |
Why?
|
| Culture Media | 1 | 2003 | 84 | 0.010 |
Why?
|
| Antibodies, Protozoan | 1 | 2004 | 77 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 2004 | 122 | 0.010 |
Why?
|
| Helicobacter pylori | 1 | 2004 | 105 | 0.010 |
Why?
|
| Canada | 1 | 2003 | 121 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 841 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 605 | 0.010 |
Why?
|
| Phodopus | 1 | 2002 | 3 | 0.010 |
Why?
|
| Survival | 1 | 2002 | 8 | 0.010 |
Why?
|
| Litter Size | 1 | 2002 | 12 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 2002 | 30 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 2002 | 30 | 0.010 |
Why?
|
| Lactation | 1 | 2002 | 38 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2004 | 252 | 0.010 |
Why?
|
| Organ Size | 1 | 2002 | 148 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 217 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2005 | 394 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2002 | 115 | 0.010 |
Why?
|
| Energy Intake | 1 | 2002 | 160 | 0.010 |
Why?
|
| Body Composition | 1 | 2002 | 146 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 650 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2002 | 167 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 404 | 0.010 |
Why?
|